Literature DB >> 26310051

Successful Oral Desensitization in a Patient With Hypersensitivity Reaction to Crizotinib.

J Sánchez-López, N Viñolas, R Muñoz-Cano, M Pascal, N Reguart, J Bartra, A Valero.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26310051

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


× No keyword cloud information.
  5 in total

1.  Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature.

Authors:  Lei Deng; Janaki Sharma; Elizabeth Ravera; Balazs Halmos; Haiying Cheng
Journal:  Lung Cancer (Auckl)       Date:  2018-09-06

2.  Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma.

Authors:  Takayo Ota; Noriyuki Masuda; Kaoru Matsui; Takao Yamada; Noriko Tanaka; Shunsuke Fujimoto; Masahiro Fukuoka
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

3.  Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report.

Authors:  Ryosuke Hirabayashi; Daichi Fujimoto; Yukari Satsuma; Masaki Hirabatake; Keisuke Tomii
Journal:  Invest New Drugs       Date:  2018-05-02       Impact factor: 3.850

4.  Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review.

Authors:  Shu-Yue Zheng; Wen Shen; Yan-Mei Peng; Hui-Juan Cui; Hua Duan; Yu-Qin Qiu; Qiang Li; Jing-Yi Zhang; Chen-Yao Sun; Xu Zhang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

5.  Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation.

Authors:  Go Makimoto; Tatsuya Nishi; Keita Kawakado; Tomoka Nishimura; Tomoki Tamura; Kenichiro Kudo; Shoichi Kuyama
Journal:  Intern Med       Date:  2020-05-26       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.